Research company Chosa Oncology has appointed Bill Cronin to lead business development and commercialization in the US in connection with the launch of Platin-DRP.Cronin will be based at the company’s office in Kendall Square in Boston and focus on relationships with pharmaceutical companies, academic cancer centers, clinical laboratories, strategic partners and opinion leaders. He will also support the planned launch of Platin-DRP for research use only, RUO.According to the press release, Cronin has more than 20 years of experience in life science, especially oncology and medical technology. He was CEO of Dignitana between 2015 and 2022 and then led the commercialization of DigniCap in the US. "After working closely with Bill for many years in connection with Dignitana’s successful expansion in the US, I have seen firsthand his ability to transform innovative Scandinavian medical technology solutions into commercially successful operations in the US market. His leadership, strategic thinking and extensive network will be invaluable assets as Chosa Oncology enters its next growth phase. We are very pleased to welcome Bill to the Chosa team", says Ingrid Atteryd Heiman, Chair of the Board of Chosa Oncology.